The Court had raised questions over the spread between purchase prices and MRP and whether the existing 16% margin cap for scheduled drugs could be extended to a wider set of medicines. The matter is scheduled for another hearing on October 12, 2026.
The Court had raised questions over the spread between purchase prices and MRP and whether the existing 16% margin cap for scheduled drugs could be extended to a wider set of medicines. The matter is scheduled for another hearing on October 12, 2026.
<iframe src="https://hindustansphere.com/embed/cluster/c6b44e55c4f74b9bd3ffd037a73b1381014df362" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Could Apollo, Fortis, Max Health Face A Profit Hit From Medicine Price Curbs? Jefferies, BofA, Macquarie Weigh In"></iframe>
